Do analysts prefer BTAI or ICCC?

BioXcel Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 1,146.32%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BTAI or SXTC?

China SXT Pharmaceuticals has higher revenue and earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 42.59 -$69.90M -$5.75 N/A China SXT Pharmaceuticals $1.14M 81.47 -$6.20M N/A N/A

Is BTAI or SXTC more profitable?

China SXT Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -11,078.53% N/A -201.53% China SXT Pharmaceuticals N/A N/A N/A

Do analysts rate AADI or BTAI?

BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 1,146.32%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

BioXcel Therapeutics (BTAI) Competitors

$0.88 0.00 (-0.54%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$0.88 0.00 (-0.18%)

As of 08:22 AM Eastern

Compare

BTAI vs. ICCC, SXTC, CGTX, AADI, and BMEA

Should you buy BioXcel Therapeutics stock or one of its competitors? MarketBeat compares BioXcel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioXcel Therapeutics include ImmuCell (ICCC), China SXT Pharmaceuticals (SXTC), Cognition Therapeutics (CGTX), Aadi Bioscience (AADI), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does BioXcel Therapeutics compare to ImmuCell?

BioXcel Therapeutics (NASDAQ:BTAI) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

ImmuCell has a net margin of -1.82% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
ImmuCell	-1.82%	-1.88%	-1.22%

BioXcel Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 1,146.32%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has higher revenue and earnings than BioXcel Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	42.59	-$69.90M	-$5.75	N/A
ImmuCell	$27.64M	3.65	-$1.04M	-$0.06	N/A

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioXcel Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, ImmuCell had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for ImmuCell and 0 mentions for BioXcel Therapeutics. ImmuCell's average media sentiment score of 0.95 beat BioXcel Therapeutics' score of 0.00 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
ImmuCell	Positive

Summary

ImmuCell beats BioXcel Therapeutics on 9 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to China SXT Pharmaceuticals?

BioXcel Therapeutics (NASDAQ:BTAI) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

China SXT Pharmaceuticals has higher revenue and earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	42.59	-$69.90M	-$5.75	N/A
China SXT Pharmaceuticals	$1.14M	81.47	-$6.20M	N/A	N/A

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for BioXcel Therapeutics. China SXT Pharmaceuticals' average media sentiment score of 0.93 beat BioXcel Therapeutics' score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
China SXT Pharmaceuticals	Positive

BioXcel Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market.

China SXT Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
China SXT Pharmaceuticals	N/A	N/A	N/A

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 1,146.32%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

China SXT Pharmaceuticals beats BioXcel Therapeutics on 9 of the 13 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Cognition Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Cognition Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	42.59	-$69.90M	-$5.75	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

In the previous week, Cognition Therapeutics' average media sentiment score of 1.00 beat BioXcel Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
Cognition Therapeutics	Positive

Cognition Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Cognition Therapeutics	N/A	-72.68%	-53.07%

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 1,146.32%. Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 251.40%. Given BioXcel Therapeutics' higher possible upside, equities research analysts plainly believe BioXcel Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

BioXcel Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Summary

Cognition Therapeutics beats BioXcel Therapeutics on 10 of the 14 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Aadi Bioscience has higher revenue and earnings than BioXcel Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.83	-$65.76M	-$2.35	N/A
BioXcel Therapeutics	$640K	42.59	-$69.90M	-$5.75	N/A

BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 1,146.32%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Aadi Bioscience has a net margin of -246.06% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aadi Bioscience had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for BioXcel Therapeutics. Aadi Bioscience's average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
BioXcel Therapeutics	Neutral

Summary

Aadi Bioscience beats BioXcel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Biomea Fusion?

BioXcel Therapeutics (NASDAQ:BTAI) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Biomea Fusion had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for Biomea Fusion and 0 mentions for BioXcel Therapeutics. Biomea Fusion's average media sentiment score of 0.35 beat BioXcel Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
Biomea Fusion	Neutral

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 1,146.32%. Biomea Fusion has a consensus price target of $8.50, suggesting a potential upside of 548.85%. Given BioXcel Therapeutics' higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

BioXcel Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biomea Fusion has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Biomea Fusion	N/A	-265.37%	-103.96%

Biomea Fusion has lower revenue, but higher earnings than BioXcel Therapeutics. Biomea Fusion is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	42.59	-$69.90M	-$5.75	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Biomea Fusion beats BioXcel Therapeutics on 10 of the 15 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTAI vs. The Competition

Export

Metric	BioXcel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.40M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.15	20.49	27.07	23.95
Price / Sales	42.59	300.33	519.31	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-0.20	7.92	10.62	6.14
Net Income	-$69.90M	$23.81M	$3.60B	$331.74M
7 Day Performance	-14.31%	-1.09%	-1.26%	-1.82%
1 Month Performance	-26.45%	2.56%	1.07%	-1.45%
1 Year Performance	-53.30%	42.16%	23.63%	16.32%

BioXcel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTAI BioXcel Therapeutics	2.1837 of 5 stars	$0.88 -0.5%	$11.00 +1,146.3%	-53.8%	$27.40M	$640K	N/A	90
ICCC ImmuCell	1.1577 of 5 stars	$10.99 -4.0%	N/A	+68.4%	$99.46M	$27.64M	N/A	70	News Coverage
SXTC China SXT Pharmaceuticals	1.0828 of 5 stars	$2.55 +0.9%	N/A	-99.0%	$97.58M	$1.14M	N/A	90	Gap Up
CGTX Cognition Therapeutics	3.0947 of 5 stars	$1.09 -0.5%	$3.33 +207.2%	+45.0%	$97.11M	N/A	N/A	20
AADI Aadi Bioscience	N/A	$3.86 -2.5%	N/A	+116.1%	$95.33M	$25.07M	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTAI) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. ICCC, SXTC, CGTX, AADI, and BMEA

How does BioXcel Therapeutics compare to ImmuCell?

Summary

How does BioXcel Therapeutics compare to China SXT Pharmaceuticals?

Summary

How does BioXcel Therapeutics compare to Cognition Therapeutics?

Summary

How does BioXcel Therapeutics compare to Aadi Bioscience?

Summary

How does BioXcel Therapeutics compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. ICCC, SXTC, CGTX, AADI, and BMEA

How does BioXcel Therapeutics compare to ImmuCell?

Is BTAI or ICCC more profitable?

Do analysts prefer BTAI or ICCC?

Which has higher valuation & earnings, BTAI or ICCC?

Do institutionals and insiders hold more shares of BTAI or ICCC?

Which has more risk and volatility, BTAI or ICCC?

Does the media prefer BTAI or ICCC?

Summary

How does BioXcel Therapeutics compare to China SXT Pharmaceuticals?

Which has better earnings & valuation, BTAI or SXTC?

Does the media refer more to BTAI or SXTC?

Which has more risk & volatility, BTAI or SXTC?

Is BTAI or SXTC more profitable?

Do insiders & institutionals believe in BTAI or SXTC?

Do analysts prefer BTAI or SXTC?

Summary

How does BioXcel Therapeutics compare to Cognition Therapeutics?

Which has preferable earnings & valuation, BTAI or CGTX?

Does the media refer more to BTAI or CGTX?

Is BTAI or CGTX more profitable?

Do institutionals & insiders hold more shares of BTAI or CGTX?

Do analysts recommend BTAI or CGTX?

Which has more volatility & risk, BTAI or CGTX?

Summary

How does BioXcel Therapeutics compare to Aadi Bioscience?

Which has better earnings and valuation, AADI or BTAI?

Do analysts rate AADI or BTAI?

Which has more volatility & risk, AADI or BTAI?

Is AADI or BTAI more profitable?

Do institutionals and insiders have more ownership in AADI or BTAI?

Does the media prefer AADI or BTAI?

Summary

How does BioXcel Therapeutics compare to Biomea Fusion?

Does the media favor BTAI or BMEA?

Do analysts recommend BTAI or BMEA?

Which has more risk & volatility, BTAI or BMEA?

Do institutionals and insiders hold more shares of BTAI or BMEA?

Is BTAI or BMEA more profitable?

Which has preferable valuation and earnings, BTAI or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools